重组人BMP6在大肠杆菌中可溶表达、纯化及活性分析

BMP6是一种调节成骨细胞和成软骨细胞分化的骨诱导因子, 在修复各种骨缺损方面具有很好的应用潜力。有诱骨活性的BMP6是多二硫键的二聚体蛋白, 疏水性极强容易聚集沉淀。为了在大肠杆菌中可溶表达具有生物活性的重组人BMP6(rhBMP6), 构建了具有TRX、GST、MBP、CBD融合标签和His6标签的 rhBMP6成熟肽原核表达载体, 调节诱导温度和IPTG浓度, 比较不同融合标签和诱导条件对目的蛋白表达量和溶解性的影响。结果表明, MBP最能有效的增强rhBMP6的溶解性, 诱导条件对溶解性影响较小。大肠杆菌BL21 trxB(DE3)这种硫氧还蛋白还原酶缺陷菌株为rhBMP6二硫键在胞质中形成提供了合适的氧化还原环境。MBP和BL21 trxB(DE3)相结合在细胞质中高效可溶表达出了BMP6融合蛋白二聚体。表达产物经亲和层析和凝胶排阻层析纯化后, 能诱导成肌细胞系C2C12向成骨细胞方向 转化。     

骨形成蛋白10成熟肽在大肠杆菌中的表达纯化及活性分析

目的:以生物制备骨形成蛋白10(BMP10)为目标,研究BMP10成熟肽在大肠杆菌中的表达及活性。方法:以人源BMP10成熟肽基因为模板,PCR获得N端带有组氨酸标签(6×His)的融合基因6×His-m BMP10,构建p ET28a/m BMP10表达载体;热击转染大肠杆菌BL21(DE3)菌株,卡那霉素抗性筛选获得重组表达菌株BL21/p ET28a-6×His-m BMP10,IPTG诱导表达后利用SDS-PAGE电泳、Western印迹对蛋白进行分析;超声波破碎菌体,收集包涵体,镍柱亲和层析纯化获得电泳纯目的蛋白;透析复性后,非还原SDS-PAGE检验目标蛋白的二聚体形成;通过体外细胞实验检测蛋白活性。结果:纯化得到纯度90%以上的m BMP10,复性后二聚体得率约为40%;活性实验测得P19细胞的Smad6蛋白表达上调3倍左右。结论:通过大肠杆菌表达体系获得具有生物活性的BMP10,为后续作用机理研究奠定了实验基础。     

棉花咖啡酸-O-甲基转移酶基因的原核表达及蛋白纯化鉴定

为获得大量高纯度的GhCOMT2蛋白以便研究其功能和性质,以pMD18-GhCOMT2质粒为模板,PCR扩增GhCOMT2基因的cDNA编码区,构建原核表达载体pET-28a-GhCOMT2,经酶切鉴定并测序后转化到大肠杆菌BL21 (DE3)中进行诱导表达,并采用Western blotting方法鉴定表达产物.结果表明:在大肠杆菌BL21(DE3)菌株中成功表达了与标签蛋白融合的GhCOMT2蛋白,大小约为40.062 kD,浓度为0.62 mg/mL.重组蛋白的最佳诱导条件为:0.2 mmol/L IPTG在16℃诱导12 h.重组蛋白以可溶形式高效表达,用蛋白标签亲和层析柱(His TrapTM HP)获得纯化重组蛋白,Western blotting分析表明其能与His多克隆抗体起特异性反应.     

D-氨基酸氧化酶与麦芽糖结合蛋白和透明颤菌血红蛋白的融合表达

D-氨基酸氧化酶(DAAO)是一种重要的工业酶。为了进一步提高DAAO在大肠杆菌中的可溶性和活性表达, 分别构建了麦芽糖结合蛋白(MBP)和透明颤菌血红蛋白与三角酵母DAAO (TvDAAO) 的N-端融合蛋白。其中, MBP融合蛋白MBP-TvDAAO在组成型(JM105/pMKC-DAAO)和诱导型菌株(JM105/pMKL-DAAO)中表达时, 目标蛋白的可溶性表达量分别达到全细胞蛋白表达量的28%以上和17%左右, 比无MBP融合的对照菌株BL21(DE3)/pET-DAAO分别提高3.7和1.8倍; 但其酶活水平显著下降。VHb融合蛋白VHb-TvDAAO在重组菌BL21(DE3)/pET-VDAAO中摇瓶诱导表达时, DAAO酶活达到了3.24 u/mL, 比对照菌株BL21(DE3)/pET-DAAO提高了约90%。     

D-氨基酸氧化酶与麦芽糖结合蛋白和透明颤菌血红蛋白的融合表达

D-氨基酸氧化酶(DAAO)是一种重要的工业酶。为了进一步提高DAAO在大肠杆菌中的可溶性和活性表达, 分别构建了麦芽糖结合蛋白(MBP)和透明颤菌血红蛋白与三角酵母DAAO (TvDAAO) 的N-端融合蛋白。其中, MBP融合蛋白MBP-TvDAAO在组成型(JM105/pMKC-DAAO)和诱导型菌株(JM105/pMKL-DAAO)中表达时, 目标蛋白的可溶性表达量分别达到全细胞蛋白表达量的28%以上和17%左右, 比无MBP融合的对照菌株BL21(DE3)/pET-DAAO分别提高3.7和1.8倍; 但其酶活水平显著下降。VHb融合蛋白VHb-TvDAAO在重组菌BL21(DE3)/pET-VDAAO中摇瓶诱导表达时, DAAO酶活达到了3.24 u/mL, 比对照菌株BL21(DE3)/pET-DAAO提高了约90%。     

人泛素结合酶9的原核表达与纯化

目的:表达和纯化高纯度的人泛素结合酶9(hUBC9)。方法:将hUBC9基因克隆到原核表达载体pGEX-6p-1上并转化大肠杆菌BL21(DE3),于30℃、1mmol/LIPTG诱导4h,表达GST-hUBC9融合蛋白。用Glutathione-Sepharose4B柱分离GST-hUBC9融合蛋白,用鼻病毒3C蛋白水解酶切去GST-hUBC9融合蛋白的GST标签,再用FPLC分子筛层析法进一步纯化hUBC9。结果和结论:获得了重组表达质粒GST-hUBC9并在大肠杆菌中可溶性表达,经亲和层析、酶切、分子筛层析后获得了可溶的、高纯度的hUBC9,为进一步研究hUBC9的功能和结构奠定了基础。     

利用同源蛋白的信号肽和前肽序列在CHO细胞中表达重组人BMP6

BMP6属于TGF-β超家族,具有较强的骨诱导作用。主要利用BMP6自身的信号肽、前肽与成熟肽基因序列构建了表达质粒pcDNA-BMP6;同时利用BMP2的信号肽、前肽与BMP6的成熟肽基因序列构建了表达质粒pcDNA-BMP2/6。将两种质粒分别瞬时转染Cos7细胞,发现质粒pcDNA-BMP2/6表达rhBMP6的效率高于质粒pcDNA-BMP6。然后将质粒pcDNA-BMP2/6与含二氢叶酸还原酶基因(dhfr)的表达质粒共转染dhfr缺陷型的中华仓鼠卵巢(CHO)细胞,经G418筛选、氨甲蝶呤(MTX)介导目的基因扩增、亚克隆后得到表达rhBMP6成熟肽的单克隆细胞株。将表达产物rhBMP6初步纯化后,能诱导前成肌细胞系C2C12向成骨细胞方向转化,显示其具有骨诱导作用。     

人乙醛脱氢酶2的原核表达及其条件优化

为实现人乙醛脱氢酶2(ALDH2)基因在原核生物中高效表达,将含有6×His标签和SUMO融合蛋白标签的人乙醛脱氢酶2基因的表达载体转化至宿主菌BL21(DE3)中。在异丙基硫代-β-D-半乳糖苷(IPTG)诱导下,目的基因在大肠杆菌内高效表达。通过对表达条件的优化,37℃使用终浓度0.3mmol/L的IPTG诱导3h,重组大肠杆菌的表达量可占全菌蛋白的16%。SUMO融合蛋白标签的加入以及较低的诱导温度(16℃)有利于提高人乙醛脱氢酶2基因在大肠杆菌内的可溶性表达。     

黄瓜CsERECTA基因的原核表达及其多克隆抗体制备

ERECTA基因编码一个富含亮氨酸重复序列结构的丝/苏氨酸类受体蛋白激酶,参与调控植物器官的形态建成,在株型控制及抗逆方面也有重要作用。该研究通过构建带有maltose binding protein(MBP)标签的pET21a-CsERECTA融合蛋白原核表达载体,实现了在大肠杆菌(E.coli)BL21(DE3)中的高效表达,并对诱导表达的温度、时间和IPTG浓度进行了优化。利用镍离子螯合层析纯化得到MBP-CsERECTA融合蛋白,再用rTEV蛋白酶对其进行酶切,得到CsERECTA蛋白并制备了该蛋白的多克隆抗体。结果表明,黄瓜CsERECTA蛋白以可溶和包涵体2种形式表达,低温有助于蛋白以可溶性形式大量存在。最佳诱导温度为23℃,诱导时间为6h,IPTG浓度为0.5mmol·L~(-1)。通过Western blot可检测到黄瓜内源的CsERECTA蛋白,说明制备的多可隆抗体具有较好的特异性。多克隆抗体的成功制备为进一步研究CsERECTA的功能奠定了基础。     

Angioarrestin(hARPl)C端FD区的克隆、表达及其免疫活性鉴定

 Angioarrestin是一种具有潜在应用价值的肿瘤血管形成抑制因子.利用DNA重组法构建了angioarrestin C端 hFD cDNA 和麦芽糖结合蛋白(MBP)重组原核表达质粒 pMAL-C2-hFD.将重组质粒转入大肠杆菌E.coli BL21（DE3）,经0.3 mmol/LIPTG 在37℃条件下诱导表达4h,SDS-PAGE 检测,融合蛋白表达量约占细菌总蛋白的20%.Western印迹证实,目的蛋白N端带有MBP标签.取表达上清纯化、透析、浓缩并冻干,以此为抗原免疫Balb/c小鼠制备多克隆抗体.此多抗可以与pET 22b（+）表达系统获得的 hFD重组蛋白发生良好的抗原抗体反应,ELISA检测多抗效价达1∶10240.实验证明：通过基因重组可获得angioarrestin C端hFD在大肠杆菌中的高效表达蛋白,且该蛋白具有较高的免疫活性.以此为抗原制备的抗angioarrestin多克隆抗体为深入研究angioarrestin提供了材料.     

Gateway vectors for the production of combinatorially-tagged His6-MBP fusion proteins in the cytoplasm and periplasm of Escherichia coli

Many proteins that accumulate in the form of insoluble aggregates when they are overproduced in Escherichia coli can be rendered soluble by fusing them to E. coli maltose binding protein (MBP), and this will often enable them to fold in to their biologically active conformations. Yet, although it is an excellent solubility enhancer, MBP is not a particularly good affinity tag for protein purification. To compensate for this shortcoming, we have engineered and successfully tested Gateway destination vectors for the production of dual His6MBP-tagged fusion proteins in the cytoplasm and periplasm of E. coli. The MBP moiety improves the yield and solubility of its fusion partners while the hexahistidine tag (His-tag) serves to facilitate their purification. The availability of a vector that targets His6MBP fusion proteins to the periplasm expands the utility of this dual tagging approach to include proteins that contain disulfide bonds or are toxic in the bacterial cytoplasm.     

Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused.

Although it is usually possible to achieve a favorable yield of a recombinant protein in Escherichia coli, obtaining the protein in a soluble, biologically active form continues to be a major challenge. Sometimes this problem can be overcome by fusing an aggregation-prone polypeptide to a highly soluble partner. To study this phenomenon in greater detail, we compared the ability of three soluble fusion partners--maltose-binding protein (MBP), glutathione S-transferase (GST), and thioredoxin (TRX)--to inhibit the aggregation of six diverse proteins that normally accumulate in an insoluble form. Remarkably, we found that MBP is a far more effective solubilizing agent than the other two fusion partners. Moreover, we demonstrated that in some cases fusion to MBP can promote the proper folding of the attached protein into its biologically active conformation. Thus, MBP seems to be capable of functioning as a general molecular chaperone in the context of a fusion protein. A model is proposed to explain how MBP promotes the solubility and influences the folding of its fusion partners.     

Comparative expression study to increase the solubility of cold adapted Vibrio proteins in Escherichia coli

Functional and structural studies require gene overexpression and purification of soluble proteins. We wanted to express proteins from the psychrophilic bacterium Vibrio salmonicida in Escherichia coli, but encountered solubility problems. To improve the solubility of the proteins, we compared the effects of six N-terminal fusion proteins (Gb1, Z, thioredoxin, GST, MBP and NusA) and an N-terminal His6-tag. The selected test set included five proteins from the fish pathogen V. salmonicida and two related products from the mesophilic human pathogen Vibrio cholerae. We tested the expression in two different expression strains and at three different temperatures (16, 23 and 37 degrees C). His6-tag was the least effective tag, and these vector constructs were also difficult to transform. MBP and NusA performed best, expressing soluble proteins with all fusion partners in at least one of the cell types. In some cases MBP, GST and thioredoxin fusions resulted in products of incorrect size. The effect of temperature is complex: in most cases level of expression increased with temperature, whereas the effect on solubility was opposite. We found no clear connection between the preferred expression temperature of the protein and the temperature of the original host organism's natural habitat.     

Crystallization of a trimeric human T cell leukemia virus type 1 gp21 ectodomain fragment as a chimera with maltose-binding protein.

We present a novel protein crystallization strategy, applied to the crystallization of human T cell leukemia virus type 1 (HTLV-1) transmembrane protein gp21 lacking the fusion peptide and the transmembrane domain, as a chimera with the Escherichia coli maltose binding protein (MBP). Crystals could not be obtained with a MBP/gp21 fusion protein in which fusion partners were separated by a flexible linker, but were obtained after connecting the MBP C-terminal alpha-helix to the predicted N-terminal alpha-helical sequence of gp21 via three alanine residues. The gp21 sequences conferred a trimeric structure to the soluble fusion proteins as assessed by sedimentation equilibrium and X-ray diffraction, consistent with the trimeric structures of other retroviral transmembrane proteins. The envelope protein precursor, gp62, is likewise trimeric when expressed in mammalian cells. Our results suggest that MBP may have a general application for the crystallization of proteins containing N-terminal alpha-helical sequences.     

High level soluble production of functional ribonuclease inhibitor in Escherichia coli by fusing it to soluble partners

Ribonuclease inhibitor (RI) is a 50-kDa cytosolic scavenger of pancreatic-type ribonucleases which inhibits ribonucleolytic activity. Expression of recombinant RI is extremely difficult to reach high levels in soluble form in the cytoplasm of Escherichia coli. Here, we utilized five N-terminal fusion partners to improve the soluble expression of RI. Among these five fusion partners which have been screened, maltose-binding protein (MBP), N-utilization substance A (NusA) and translation initiation factor 2 domain I (IF2) have greatly improved the soluble expression level of recombinant murine RI under the drive of T7 promoter, while glutathione S-transferase (GST) and small ubiquitin modifying protein (SUMO) were much less efficient. All these RI-fusion proteins remained to be highly active in inhibiting RNase A activity. Furthermore, all fusion tags can be efficiently removed by enterokinase digestion to generate native RI which results the highest yield to date (>30mg of native RI per liter culture). And a convenient two-step immobilized metal affinity chromatography (IMAC) method has been implemented in our study, comparing with the traditional RNase A affinity chromatography method.     

Recombinant BMP 4/7 fusion protein induces differentiation of bone marrow stem cells

Bone morphogenetic proteins (BMPs) induce differentiation of mesenchymal cells to cartilage and bone. We cloned BMP4 and BMP7 cDNAs from human placenta and fetal cartilage cells, respectively, and used an Escherichia coli expression system to produce recombinant BMP4 and BMP4/7 proteins. Differentiation of primary cultures of bone marrow stem cells (BMSC) treated with BMP4 or BMP4/7 was evaluated by Von Kossa staining and by determining alkaline phosphatase activity and osteocalcin level. BMP4/7-induced BMSC differentiation more potently than BMP4. We showed that BMP4/7 fusion protein expressed in E. coli is biologically active and is a novel strategy to treat bone injury in a clinical setting.     

Optimized expression, solubilization and purification of nuclear inclusion protein b of cardamom mosaic virus

All RNA viruses encode an RNA-dependent RNA polymerase (RdRP) that is required for replication of the viral genome. Nuclear inclusion b (NIb) gene codes for the RdRp in Potyviridae viruses. In this study, expression, solubilization and purification of NIb protein of Cardamom mosaic virus (CdMV) is reported. The objective of the present study was to express and purify the NIb protein of CdMV on a large scale for structural characterization, as the structure of the RdRp from a plant virus is yet to be determined. However, the expression of NIb protein with hexa-histidine tag in Escherichia coli led to insoluble aggregates. Out of all the approaches [making truncated versions to reduce the size of protein; replacing an amino acid residue likely to be involved in hydrophobic intermolecular interactions with a hydrophilic one; expressing the protein along with chaperones; expression in Origami cells for proper disulphide bond formation, in E. coli as a fusion with maltose-binding protein (MBP) and in Nicotiana tabacum] to obtain the RdRp in a soluble form, only expression in E. coli as a fusion with MBP and its expression in N. tabacum were successful. The NIb expressed in plant or as a fusion with MBP in E. coli can be scaled up for further work.